Related Experiment Video
Updated: Jun 9, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Burden of cardiovascular disease attributable to metabolic risks in 204 countries and territories from 1990 to 2021
Huimin Chen1,2, Lu Liu1,2, Yi Wang1,2
1D epartment of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Hangzhou 310009, China.
Aims:
To evaluate the global cardiovascular disease (CVD) burden attributable to metabolic risks in 204 countries and territories from 1990 to 2021.
Methods And Results:
Following the methodologies used in the Global Burden of Disease Study 2021, this study analysed CVD deaths and disability-adjusted life-years (DALYs) attributable to metabolic risks by location, age, sex, and Socio-demographic Index (SDI). In 2021, metabolic risks accounted for 13.59 million CVD deaths (95% UI 12.01-15.13) and 287.17 million CVD DALYs (95% UI 254.92-316.32) globally, marking increases of 63.3% and 55.5% since 1990, respectively. Despite these increases, age-standardized mortality and DALY rates have significantly declined. The highest age-standardized rates of metabolic risks-attributable CVD mortality and DALYs were observed in Central Asia and Eastern Europe, while the lowest rates were found in High-income Asia Pacific, Australasia, and Western Europe, all of which are high SDI regions. Among the metabolic risks, high systolic blood pressure emerged as the predominant factor, contributing to the highest numbers of CVD deaths [10.38 million (95% UI 8.78-12.03)] and DALYs [14.52 million (95% UI 180.42-247.57)] in 2021, followed by high LDL cholesterol.
Conclusion:
Our study highlights the persistent and significant impact of metabolic risks on the global CVD burden from 1990 to 2021, emphasizing the need of designing public health strategies that align with regional healthcare capacities and demographic differences to effectively reduce these effects through enhanced international collaboration and specific policies.
More Related Videos
Related Concept Videos
Coronary Artery Disease I: Introduction
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease IV: Medical Management
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Obesity

